EIF4A2 and melanoma: These results suggested that eIF4A inhibition, in combination with BRAFi/MEKi, either impeded the transition of parental cells towards persister cells or selectively targeted persister cells, and that combining eIF4A inhibition with BRAFi/MEKi could be a promising strategy to overcome the challenge of targeting heterogeneous melanoma cell populations and eventually abrogate the emergence of resistant cells.